Tag Archives: Oxbryta

GBT chief blames COVID-19 for ‘clear’ slowdown in Oxbryta launch, but analysts are still impressed

Global Blood Therapeutics’ sickle cell disease medicine Oxbryta got off to a hot start after a November FDA approval. But early in its launch, execs now say they’re seeing a “clear headwind” from the COVID-19 pandemic. About 2,000 patients have been prescribed the new drug in the early months of the rollout. But lately, new patient… Read More »

FDA Approves Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease

FDA Approves Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease Print this page SOUTH SAN FRANCISCO, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) —  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta™ (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children… Read More »